Table 1.
Criteria of division and anamnestic information for volunteering subjects, sorted after they completed a questionnaire. [No: number; yrs: years; m: males; f: female].
| Infection/ Vaccine |
Age | Gender | No | Schedule | Period | Antibody Monitoring | |
|---|---|---|---|---|---|---|---|
| Group 1 | COVID-19 infection | 43 ± 18 yrs | m 57 (46 ± 17 yrs) f 76 (41 ± 18 yrs) | 133 | Previous SARS-CoV-2 infection | April 2020 and September 2021 | From 1st month since negative swab to 9 months after |
| Group 2 | Pfizer BioNTech | 49 ± 18 yrs | m 85 (53 ± 17 yrs) f 87 (46 ± 17 yrs) | 172 | Double dose of Pfizer-BioNTech Cominarty (BNT162b2) vaccine | 2nd dose: 21 days later | Since administration of 2nd dose |
| Group 3 | ChadOx1 nCoV19 | 59 ± 13 yrs | m 17 (53 ± 14 yrs) f 21 (63 ± 10 yrs) | 38 | Double dose of Vaxzevria (ChAdOx1-S) AstraZeneca) vaccine | 2nd dose: 4–12 weeks after | Since administration of 2nd dose |
| Group 4 | ChadOx1 nCoV19 + Pfizer BioNTech/heterologous | 43 ± 14 yrs | m 16 (43 ± 16 yrs) f 15 (42 ± 10 yrs) | 32 | First dose (priming) of the vaccine Vaxzevria (ChAdOx1-S) AstraZeneca and a second dose (booster) of the vaccine Cominarty (BNT162b2) Pfizer-BioNTech | Booster dose: 8–12 weeks from the priming (since the ministerial circular of 14 June 2021) | Since administration of booster dose |
| Group 5 | COVID-19 infection + booster dose | 44 ± 17 yrs | m 10 (52 ± 15 yrs) f 18 (40 ± 17) yrs | 28 | Previous SARS-CoV-2 infection and a single dose of anti-SARS-CoV-2/COVID19 vaccine (in this study with Cominarty (BNT162b2) Pfizer-BioNTech preparation) | Vaccine between 4–8 months since infection | Since administration of vaccine |